SHANDONG XINHUA (00719) announced that the company has recently received the Drug Registration Certificate for Sacubitril Valsartan Sodium Tablets (hereinafter referred to as "the product") issued by the National Medical Products Administration of China.

Sacubitril Valsartan Sodium Tablets are indicated for adult patients with chronic heart failure with reduced ejection fraction (NYHA Class II-IV, LVEF ≤40%) to reduce the risk of cardiovascular death and heart failure hospitalization. The tablets can replace angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor antagonists (ARB) and be used in combination with other heart failure treatment medications. Sacubitril Valsartan Sodium Tablets are also indicated for the treatment of primary hypertension.

As a compound drug containing angiotensin II receptor antagonists, this product is classified as a Category B variety in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2025). According to relevant statistical data, the sales revenue of Sacubitril Valsartan Sodium Tablets in Chinese public medical institutions reached approximately RMB 4.9 billion in 2024.

SHANDONG XINHUA obtained the drug registration certificate for Sacubitril Valsartan Sodium Tablets in August 2025, which will help enrich the company's cardiovascular disease treatment drug portfolio and enhance its comprehensive competitive advantages.